3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
17
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
7
Endometrial Neoplasms
4
Lymphoma, T-Cell, Peripheral
3
Glioblastoma
3
Colorectal Neoplasms
3
Sarcoma
2
Primary Myelofibrosis
2
Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Squamous Cell
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Richter's Transformation
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
4
Pemetrexed
3
Paclitaxel
3
Fulvestrant
2
FANG vaccine
2
Drug Therapy
2
Carboplatin
2
tucatinib
1
trastuzumab deruxtecan
1
seribantumab
1
selinexor
1
osimertinib
1
gedatolisib
1
dactolisib
1
cobimetinib
1
cemiplimab
1
atezolizumab
1
Watchful Waiting
1
Trastuzumab
1
Transurethral Resection of Prostate
1
Trabectedin
1
Therapeutics
1
Sutures
1
Radiation
1
Quality of Life
1
Pregnancy Tests
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
OSI 930
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Neoplasms
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled